Clinical Neurology and Neurosurgery
Volume 112, Issue 6 , Pages 463-466 , July 2010

Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine

Received 28 April 2009 ,Revised 21 January 2010 ,Accepted 7 February 2010.

References 

  1. Subcomitę of Classification of the Headaches of the International Headache Society. Migraine. In Alaúde Editorial Ltda (Ed.), The International Clasification of Headache Disorders – ICHD-II. Săo Paulo, 2006. p. 41–66.
  2. Campo-Arias A. Antidepressants in migraine prophylaxis: an approximation. Rev Neurol. 2004;38(9):864–868
  3. Cerbo R, Barbanti P, Fabbrini G, Pascali MP, Catarci T. Amitriptyline is effective in chronic but not in episodic tension-type headache: pathogenetic implications. Headache. 1998;38(6):453–457
  4. Couch JR, Ziegler DK, Hassanein R. Amitriptyline in the prophylaxis of migraine. Effectiveness and relationship of antimigraine and antidepressant effects 149. Neurology. 1976;26(2):121–127
  5. Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis: changes in pattern of attacks during a controlled clinical trial 153. J Neurol Neurosurg Psychiatry. 1973;36(4):684–690
  6. Ramadan NM, Schultz LL, Gilkey SJ. Migraine prophylactic drugs: proof of efficacy, utilization and cost. Cephalalgia. 1997;17(2):73–80
  7. Olesen J. Understanding the biologic basis of migraine. N Engl J Med. 1994;331(25):1713–1714
  8. Blau JN. Migraine: theories of pathogenesis. Lancet. 1992;339(8803):1202–1207
  9. Moskowitz MA, Cutrer FM. CGRP: blood flow and more?. Cephalalgia. 1996;16(5):287
  10. Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Microsc Res Technol. 2001;53(3):167–178
  11. Durham PL. CGRP receptor antagonists: a new choice for acute treatment of migraine?. Curr Opin Invest Drugs. 2004;5(7):731–735
  12. Dressler D, Saberi FA, Barbosa ER. Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr. 2005;63(1):180–185
  13. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004;44(1):35–42
  14. Bach-Rojecky L, Lackovic Z. Central origin of the antinociceptive action of botulinum toxin type A. Pharmacol Biochem Behav. 2009;94(2):132–138
  15. Menezes C, Rodrigues B, Magalhaes E, Melo A. Botulinum toxin type A in refractory chronic migraine: an open-label trial. Arq Neuropsiquiatr. 2007;65(3A):596–598
  16. Mathew NT, Kailasan J, Meadors L. Preditors of response to botulinum toxin type A (BoNTA) in chronic daily headache. Headache. 2008;48(2):194–200
  17. Conway S, Delplanche C, Crowder J, Rothock J. Botox therapy for refractory chronic migraine. Headache. 2005;45(4):355–357
  18. Freitag FG, Diamond S, Diamond M, Urban G. Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache. 2008;48(2):201–209
  19. Evers S, Vollmer-Haase J, Schwaag S, et al. Botulinum toxin A in the prophylactic treatment of migraine—a randomized, double-blind, placebo-controlled study. Cephalalgia. 2004;24(10):838–843
  20. Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache. 2008;48(2):210–220

PII: S0303-8467(10)00036-3

doi: 10.1016/j.clineuro.2010.02.004

Clinical Neurology and Neurosurgery
Volume 112, Issue 6 , Pages 463-466 , July 2010

Article Tools

* Image Usage & Resolution